alprostadil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 138 745-65-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • alprostadil
  • prostaglandin E1
  • vasaprostan
  • PGE1
  • prostavasin
A potent vasodilator agent that increases peripheral blood flow.
  • Molecular weight: 354.49
  • Formula: C20H34O5
  • CLOGP: 2.50
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 94.83
  • ALOGS: -3.65
  • ROTB: 13
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg P
20 mcg P
0.25 mg urethral

ADMET properties:

PropertyValueReference
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 45.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 49
kinase-selectivity-class AXL,BRAF,EIF2AK3,EPHB4,GRK2,MAP2K6,STK33,TEK 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 1981 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incision site pain 52.94 36.88 10 1212 1368 90625857
Lymphocyte count decreased 51.80 36.88 19 1203 35031 90592194
Red blood cells urine positive 44.46 36.88 10 1212 3215 90624010
Blood urea increased 43.13 36.88 16 1206 30397 90596828
Capillary leak syndrome 40.44 36.88 9 1213 2758 90624467
Arm amputation 40.44 36.88 5 1217 37 90627188
Haematotoxicity 39.38 36.88 12 1210 12523 90614702
Neutrophil count increased 38.11 36.88 13 1209 19377 90607848

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 196.79 21.52 254 3436 629943 41987702
Priapism 153.64 21.52 45 3645 6362 42611283
Erection increased 146.32 21.52 27 3663 484 42617161
Incision site pain 142.21 21.52 33 3657 1870 42615775
Lymphocyte count decreased 135.80 21.52 60 3630 27749 42589896
Product quality issue 115.24 21.52 47 3643 17835 42599810
Neutrophil count increased 91.08 21.52 41 3649 19763 42597882
Red blood cells urine positive 90.74 21.52 23 3667 1887 42615758
Penile pain 87.27 21.52 22 3668 1766 42615879
Blood urea increased 74.20 21.52 42 3648 32751 42584894
Painful erection 59.79 21.52 12 3678 339 42617306
Device malfunction 58.17 21.52 26 3664 12301 42605344
Protein urine present 57.96 21.52 21 3669 5780 42611865
Device failure 55.88 21.52 17 3673 2726 42614919
Blood glucose increased 53.46 21.52 47 3643 73652 42543993
Procedural pain 47.03 21.52 18 3672 5761 42611884
Haemoglobin decreased 42.95 21.52 55 3635 132416 42485229
White blood cell count increased 39.34 21.52 32 3658 45055 42572590
Wrong technique in product usage process 38.76 21.52 31 3659 42604 42575041
Foreign body in reproductive tract 38.31 21.52 5 3685 5 42617640
Bilirubin conjugated increased 35.57 21.52 13 3677 3664 42613981
Penile burning sensation 35.10 21.52 5 3685 14 42617631
Drug reaction with eosinophilia and systemic symptoms 34.89 21.52 29 3661 42046 42575599
Cytomegalovirus viraemia 31.01 21.52 16 3674 10361 42607284
Complications of transplanted kidney 30.83 21.52 13 3677 5337 42612308
Harlequin skin reaction 29.03 21.52 4 3686 8 42617637
Infantile apnoea 27.30 21.52 8 3682 1128 42616517
Systolic hypertension 25.77 21.52 6 3684 344 42617301
Cardiac septal hypertrophy 24.95 21.52 6 3684 395 42617250
Kidney transplant rejection 24.83 21.52 13 3677 8670 42608975
Needle issue 24.76 21.52 13 3677 8714 42608931
Penile haemorrhage 23.58 21.52 7 3683 1031 42616614
Penile size reduced 23.01 21.52 5 3685 209 42617436
Therapeutic product effect decreased 22.59 21.52 22 3668 39128 42578517

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incision site pain 211.40 23.16 43 4078 3092 110582086
Lymphocyte count decreased 205.57 23.16 78 4043 57165 110528013
Neutrophil count increased 145.49 23.16 53 4068 34599 110550579
Priapism 143.05 23.16 35 4086 5826 110579352
Red blood cells urine positive 131.83 23.16 32 4089 5153 110580025
Blood urea increased 131.68 23.16 56 4065 54901 110530277
Venoocclusive disease 120.49 23.16 31 4090 6319 110578859
Haemoglobin decreased 100.15 23.16 79 4042 248648 110336530
Protein urine present 89.59 23.16 28 4093 11456 110573722
Penile pain 84.30 23.16 17 4104 1167 110584011
White blood cell count increased 77.48 23.16 47 4074 96795 110488383
Drug ineffective 67.30 23.16 163 3958 1520377 109064801
Blood glucose increased 66.33 23.16 48 4073 132448 110452730
Erection increased 55.81 23.16 10 4111 363 110584815
Drug reaction with eosinophilia and systemic symptoms 48.65 23.16 33 4088 82062 110503116
Complications of transplanted kidney 45.16 23.16 15 4106 7427 110577751
Kidney transplant rejection 41.73 23.16 16 4105 11971 110573207
Procedural pain 41.18 23.16 22 4099 35543 110549635
Bilirubin conjugated increased 39.59 23.16 13 4108 6211 110578967
Painful erection 39.57 23.16 7 4114 236 110584942
Gastrointestinal infection 39.32 23.16 16 4105 13989 110571189
Cytomegalovirus viraemia 38.87 23.16 17 4104 17747 110567431
Product quality issue 38.64 23.16 28 4093 77271 110507907
Haematotoxicity 36.08 23.16 17 4104 21065 110564113
Blood albumin decreased 34.55 23.16 18 4103 27634 110557544
Penile burning sensation 33.13 23.16 4 4117 6 110585172
Alanine aminotransferase increased 32.38 23.16 37 4084 183736 110401442
Cystitis haemorrhagic 31.06 23.16 13 4108 12196 110572982
Hepatic function abnormal 30.84 23.16 26 4095 89269 110495909
Cardiac septal hypertrophy 29.87 23.16 6 4115 403 110584775
High density lipoprotein decreased 28.69 23.16 10 4111 5723 110579455
Arm amputation 28.48 23.16 5 4116 161 110585017
Blood triglycerides increased 28.26 23.16 15 4106 23911 110561267
Penile haemorrhage 25.11 23.16 6 4115 902 110584276
Systolic hypertension 24.75 23.16 6 4115 958 110584220
Acute graft versus host disease 23.94 23.16 11 4110 12870 110572308
Delayed graft function 23.53 23.16 8 4113 4249 110580929

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EA01 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Prostaglandins
ATC G04BE01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs used in erectile dysfunction
FDA CS M0017805 Prostaglandins
FDA MoA N0000000106 Prostaglandin Receptor Agonists
FDA PE N0000009059 Genitourinary Arterial Vasodilation
FDA PE N0000009911 Venous Vasodilation
FDA EPC N0000175454 Prostaglandin Analog
MeSH PA D002317 Cardiovascular Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D014665 Vasodilator Agents
MeSH PA D064804 Urological Agents
FDA EPC N0000180189 Prostaglandin E1 Agonist
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

G04BE Drugs used in erectile dysfunction 9 drugs
apomorphineavanafilmoxisylytepapaverinesildenafiltadalafiludenafilvardenafilyohimbine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Coarctation of aorta indication 7305005
Congenital atresia of tricuspid valve indication 63042009
Tetralogy of Fallot indication 86299006 DOID:6419
Pulmonary artery stenosis indication 95441000
Congenital atresia of the pulmonary valve indication 204342004
Ebstein's anomaly of tricuspid valve indication 204357006 DOID:14289
Impotence indication 397803000
Aorta Dextratransposition with Intact Ventricular Septum indication
Congenital Heart Defect Requiring Open Patent Ductus Arteriosus indication
Pulmonary hypertension off-label use 70995007 DOID:6432
Peripheral vascular disease off-label use 400047006
Apnea contraindication 1023001
Induratio penis plastica contraindication 1335005 DOID:8616
Priapism contraindication 6273006 DOID:9286
Thrombocytosis contraindication 6631009 DOID:2228
Sickle cell trait contraindication 16402000
Disorder of lung contraindication 19829001 DOID:850
Urethritis contraindication 31822004 DOID:1343
Fibrosis of corpus cavernosum contraindication 32608004
Balanitis contraindication 44882003 DOID:13033
Low blood pressure contraindication 45007003
Respiratory distress syndrome in the newborn contraindication 46775006
Blood coagulation disorder contraindication 64779008 DOID:1247
Urethral stricture contraindication 76618002
Leukemia, disease contraindication 93143009 DOID:1240
Multiple myeloma contraindication 109989006 DOID:9538
Penis implantation contraindication 119996002
Hb SS disease contraindication 127040003 DOID:10923
Erythrocytosis contraindication 127062003
Lymphoid leukemia contraindication 188725004 DOID:1037
Pyloric obstruction contraindication 244815007
Penis bent contraindication 249247007
Deformity of Erection of the Penis contraindication
Hypospadia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.76 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST EC50 8 WOMBAT-PK CHEMBL
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST EC50 6.80 WOMBAT-PK CHEMBL
Prostacyclin receptor GPCR EC50 7.50 WOMBAT-PK
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST EC50 8.80 WOMBAT-PK
Prostaglandin D2 receptor GPCR EC50 7.30 WOMBAT-PK
Cation channel sperm-associated protein 1 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 2 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 3 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Cation channel sperm-associated protein 4 Ion channel ACTIVATOR EC50 6.30 IUPHAR
Nuclear receptor subfamily 4 group A member 2 Nuclear other EC50 5.52 CHEMBL
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST EC50 9 WOMBAT-PK
Prostaglandin E2 receptor EP1 subtype GPCR Ki 8.22 CHEMBL
Prostaglandin E2 receptor EP2 subtype GPCR Ki 7.66 CHEMBL
Prostaglandin E2 receptor EP3 subtype GPCR Ki 8.30 CHEMBL
Prostaglandin E2 receptor EP4 subtype GPCR Ki 8.51 CHEMBL
Prostaglandin E2 receptor EP2 subtype GPCR AGONIST Ki 8 IUPHAR
Prostaglandin E2 receptor EP4 subtype GPCR AGONIST Ki 9.20 IUPHAR
Prostacyclin receptor GPCR AGONIST Ki 7.50 IUPHAR
Prostaglandin E2 receptor EP3 subtype GPCR AGONIST EC50 9.35 IUPHAR
Prostaglandin E2 receptor EP1 subtype GPCR AGONIST Ki 7 IUPHAR

External reference:

IDSource
4018099 VUID
N0000146437 NUI
D00180 KEGG_DRUG
598 RXNORM
C0002335 UMLSCUI
CHEBI:15544 CHEBI
XPG PDB_CHEM_ID
CHEMBL495 ChEMBL_ID
DB00770 DRUGBANK_ID
D000527 MESH_DESCRIPTOR_UI
5280723 PUBCHEM_CID
4425 INN_ID
F5TD010360 UNII
11600 MMSL
4154 MMSL
d01387 MMSL
4018099 VANDF
000704 NDDF
109119001 SNOMEDCT_US
48988008 SNOMEDCT_US
F5TD010360 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PROSTINVR PEDIATRIC HUMAN PRESCRIPTION DRUG LABEL 1 0009-0215 INJECTION, SOLUTION 500 ug INTRAVENOUS NDA 17 sections
PROSTINVR PEDIATRIC HUMAN PRESCRIPTION DRUG LABEL 1 0009-3169 INJECTION, SOLUTION 500 ug INTRAVENOUS NDA 17 sections
Caverject HUMAN PRESCRIPTION DRUG LABEL 1 0009-3701 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20.50 ug INTRACAVERNOUS NDA 29 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 0009-5181 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 ug INTRACAVERNOUS NDA 27 sections
Caverject Impulse HUMAN PRESCRIPTION DRUG LABEL 1 0009-5182 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 ug INTRACAVERNOUS NDA 27 sections
Caverject HUMAN PRESCRIPTION DRUG LABEL 1 0009-7686 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 41.10 ug INTRACAVERNOUS NDA 29 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-010 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 ug INTRACAVERNOUS NDA 23 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-020 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 ug INTRACAVERNOUS NDA 23 sections
Edex HUMAN PRESCRIPTION DRUG LABEL 1 52244-040 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 40 ug INTRACAVERNOUS NDA 23 sections
Alprostadil HUMAN PRESCRIPTION DRUG LABEL 1 71288-206 INJECTION, SOLUTION, CONCENTRATE 500 ug INTRAVASCULAR ANDA 16 sections